Maha Othman – ”BIC 2025 is Without a Doubt a Remarkable Scientific Event — and I’m Excited for What Lies Ahead!”
Maha Othman, Editor-in-Chief of Current Opinion in Hematology Journal, Research Co-Lead at CanVECTOR Research Network, shared on LinkedIn:
”Just returned from my first BIC – and what an experience!
A niche and well-organized conference, BIC 2025 brought together cutting-edge science, rich discussions, and an inspiring community of experts — all set in the beautiful city of Padua.
I had the opportunity to present novel AI-driven data on G14, a potent peptide inhibitor that disrupts the Platelet–VWF interaction.
This research has promising diagnostic and therapeutic potential in PT-VWD and Type 2B VWD; two bleeding disorders.
Proud to share that this collaborative work — between my lab at Queen’s University ’, Thomas Kazmirchuk, Ashkan Golshani Lab at Carleton University — has just been published in Blood Advances.
It was also a pleasure catching up with so many respected colleagues mentors and brilliant minds in the field — Glenn F. Pierce, David Lillicrap, Bernhard Lämmle, Augusto Federici, Cécile Denis, Caterina Casari, Edward Tuddenham, Wolfgang Miesbach …many others and meet rising stars/ make new friends like Gregory Newby, Alexander Tischer and Mathew Auton.
Akso got a chance to see/ experience a glimpse of the fascinating Italian culture , food and architecture Venice, Padua
A special thanks to Flora Peyvandi for decades of research and leadership in this field, and to the BIC organizing committee for the kind invitation.
Always grateful to St. Lawrence College for supporting professional development and quality research.
Thanks to all my students waiting for me to come back to resume our teaching / learning journey and career building!
BIC 2025 is without a doubt a remarkable scientific event — and I’m excited for what lies ahead!”

More from BIC 2025 featured in Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation